Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 2,089 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $7.45, for a total value of $15,563.05. Following the sale, the executive vice president directly owned 157,529 shares in the company, valued at approximately $1,173,591.05. This represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Stock Up 27.7%

Shares of VIR traded up $2.06 on Tuesday, hitting $9.49. The company’s stock had a trading volume of 38,240,174 shares, compared to its average volume of 1,972,225. The firm’s fifty day moving average price is $6.80 and its 200-day moving average price is $5.99. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.29. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The company’s quarterly revenue was up 417.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.76) earnings per share. As a group, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on VIR shares. Evercore reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. Needham & Company LLC boosted their price target on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Vir Biotechnology in a research report on Tuesday. Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price for the company in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $19.88.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of VIR. Raymond James Financial Inc. bought a new position in Vir Biotechnology during the second quarter worth about $35,000. FNY Investment Advisers LLC acquired a new position in shares of Vir Biotechnology during the 3rd quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the period. UMB Bank n.a. raised its position in shares of Vir Biotechnology by 1,418.7% in the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after buying an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after buying an additional 4,899 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.